Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation

Ruth Pettengell, Norbert Schmitz, Christian Gisselbrecht, Graeme Smith, William N Patton, Bernd Metzner, Dolores Caballero, Herve Tilly, Jan A Walewski, Isabelle Bence-Bruckler, Bik To, Christian H Geisler, Rik Schots, Eva Kimby, Christian J Taverna, Tomás Kozák, Peter Dreger, Ruzena Uddin, Carmen Ruiz de Elvira, Anthony H Goldstone

    110 Citationer (Scopus)

    Abstract

    The objective of this randomized trial was to assess the efficacy and safety of rituximab as in vivo purging before transplantation and as maintenance treatment immediately after high-dose chemotherapy and autologous stem-cell transplantation (HDC-ASCT) in patients with relapsed follicular lymphoma (FL).
    OriginalsprogEngelsk
    TidsskriftJournal of clinical oncology : official journal of the American Society of Clinical Oncology
    Vol/bind31
    Udgave nummer13
    Sider (fra-til)1624-30
    Antal sider7
    ISSN0732-183X
    DOI
    StatusUdgivet - 1 maj 2013

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation'. Sammen danner de et unikt fingeraftryk.

    Citationsformater